RX CompoundedRxMonitor

Entity monitoring profile

Nephron Pharmaceuticals Verification and Monitoring Profile

Federal 503B registration status for Nephron Pharmaceuticals, checked against the complete FDA register, with the open fields that remain.

Direct answer

A registration carrying the Nephron name appears on FDA's outsourcing facility list, but the registered legal name differs from Nephron Pharmaceuticals and corporate identity has not been confirmed. This is recorded as a name match rather than a verified identity — treating them as the same entity without corporate records would be an inference this platform does not make. No inspection outcome, Form 483, warning letter, recall, or disciplinary record has been verified for this entity, so none is published.

Key findings

  • Federal 503B registration: Name match on the 503B register; legal identity unconfirmed.
  • A Nephron-named outsourcing facility is registered in West Columbia, South Carolina. The registered legal name differs from Nephron Pharmaceuticals, so this is recorded as a corporate-family match rather than a verified identity.
  • Registration means FDA received the required filing — it is not approval and not a CGMP finding.
  • No inspection outcome, Form 483, warning letter, recall or disciplinary record is verified for this entity.
  • Checked against the complete FDA register of 96 outsourcing facility registrations.
Nephron Pharmaceuticals — federal register check and verification state (11 fields open)
Entity name as publishedNephron Pharmaceuticals
Federal 503B registrationConflicting Evidence Name match on the 503B register; legal identity unconfirmed
Registered site(s) on FDA list
  • Nephron Sterile Compounding Center, LLC (NSCC) — West Columbia, SC
Registry checked against96 registrations, FDA list, 2026-07-23
Operating modelWidely identified as a registered 503B outsourcing facility; registration to be confirmed against the current FDA list.
State licence and numberVerification Pending
Nonresident licencesVerification Pending
FDA inspection historyVerification Pending
Form 483 observationsVerification Pending
Warning lettersVerification Pending
Most recent action statusVerification Pending
Recalls (current)Verification Pending
Recalls (historical)Verification Pending
State disciplinary recordsVerification Pending
AccreditationsVerification Pending
OwnershipVerification Pending
Evidence status Conflicting Evidence
Verified 2026-07-23
Reviewer CompoundedRxMonitor Regulatory Desk
Snapshot 2026-07-23
Methodology v1.0
Sources checked FDA register (96 registrations) + 10 framework sources
What this status does and does not mean. Absence from the register means this entity is not a federally registered outsourcing facility. That is normal and lawful: Compounders operating under section 503A can only distribute compounded drugs based on receipt of valid prescriptions for identified individual patients. Outsourcing facilities may or may not receive patient-specific prescriptions. FDA

Federal registration status

A Nephron-named outsourcing facility is registered in West Columbia, South Carolina. The registered legal name differs from Nephron Pharmaceuticals, so this is recorded as a corporate-family match rather than a verified identity.

Registration and inspections are facility specific. Facilities under common ownership and control are inspected individually. Before purchasing, FDA advises determining that the specific facility in which the drugs are compounded is an outsourcing facility with a satisfactory inspection. FDA

FDA-registered outsourcing facility entries matching Nephron Pharmaceuticals
Registered facility nameLocation
Nephron Sterile Compounding Center, LLC (NSCC)West Columbia, SC
Compounded GLP-1 regulatory position. Both the tirzepatide and semaglutide shortages are resolved and FDA has proposed excluding both from the 503B bulks list. The full verified timeline, with sources, is maintained on the alerts and enforcement hub.

What this means

  • The full federal register was checked and the result is stated with its date.
  • Absence is reported as absence from a named list, not as a finding.
  • The state board holds the licence record that would complete this profile.

What this does not mean

  • That this entity is compliant, safe, or non-compliant — none is asserted.
  • That federal registration constitutes approval or a CGMP finding.
  • That absence from this list indicates any problem — it does not.

What can and cannot be established about Nephron Pharmaceuticals today?

Verification of a compounding entity runs across two separate systems that do not talk to each other. The federal system covers outsourcing facilities only: registration, CGMP inspection, Form 483 observations, warning letters and recalls. The state system covers licensure, scope of permitted compounding, and discipline — and it is the only system that covers 503A pharmacies at all.

For Nephron Pharmaceuticals, the federal side is settled at this snapshot: name match on the 503b register; legal identity unconfirmed. The state side is not, and that is where the remaining evidentiary weight sits.

The two verification systems as they apply to Nephron Pharmaceuticals
QuestionSystem that answers itStatus for this entity
Is it federally registered as a 503B facility?FDA outsourcing facility registerConflicting Evidence
Is its state pharmacy licence current?State board of pharmacyVerification Pending
Is it permitted to compound sterile preparations?State board permit classVerification Pending
Has FDA inspected it, and what was found?FDA inspection recordsVerification Pending
Are there Form 483 observations?FDA inspection recordsVerification Pending
Is there an active warning letter?FDA warning letter databaseVerification Pending
Any current or historical recalls?FDA enforcement reportsVerification Pending
Any state disciplinary action?State board ordersVerification Pending

What a buyer should do with this record

This page settles one question and names the records that settle the rest. It is a starting point for verification, not a substitute for it.

If a programme names Nephron Pharmaceuticals as its dispensing pharmacy, the next step is the state board register — that confirms whether the licence is current today, which no snapshot can. Then, if a 503B claim is made, confirm it against the FDA register directly rather than accepting the claim.

What remains open for Nephron Pharmaceuticals

With Nephron Pharmaceuticals absent from the federal register, the entire evidentiary weight falls on state records. The board of pharmacy in its resident state holds the licence, the scope of permitted compounding, and any disciplinary history.

To determine whether a registered outsourcing facility has been the subject of a state enforcement action, FDA directs the public to check with the State Board of Pharmacy for the state in which the facility is located. FDA

The method used for each field, and why none of it can be inferred, is set out on the methodology page. Sector-level context on the gap between registration and inspection is on the monitoring hub.

Limitations of this record.
  • Checked against FDA's register of 96 registrations on 2026-07-23; FDA updates the list weekly.
  • Self-reported registration information on FDA's list has not been verified by FDA.
  • State licensure, inspection outcomes and enforcement records have not been checked for this entity.
  • Sector statistics describe the 503B population, not this entity.
Sources checked for this entity — 5 sources
Right to respond. If Nephron Pharmaceuticals believes any record on this page is inaccurate, incomplete, or out of date, it may submit a response through the right-to-respond process. Responses are published alongside the record without edit to their substance, and any accepted correction is logged in the update history above with its date.
Where the detail lives. The six parties in a compounded prescription, and which register holds each, are set out on the provider–pharmacy relationships page. The eight items to establish before paying any programme are listed on the patient safety page.

Section hub: Pharmacy profiles · Methodology · Status definitions · Right to respond

Frequently asked questions

Is Nephron Pharmaceuticals on the FDA 503B register?

A registration carrying the Nephron name appears — Nephron Sterile Compounding Center, LLC (NSCC) (West Columbia, SC) — but the registered legal name differs and corporate identity has not been confirmed.

Why is this recorded as a name match rather than a confirmed registration?

Because treating a similar trading name as the same legal entity would be an inference. Corporate records would be needed to establish identity, and they have not been checked.

What would confirm whether Nephron Pharmaceuticals holds the registration?

State corporate filings or the entity's own confirmation, matched against the registered legal name on FDA's list.

Does the name match imply anything about Nephron Pharmaceuticals?

No. It is a data-matching state, not a finding of any kind.

Can Nephron Pharmaceuticals still compound semaglutide or tirzepatide?

Both shortages are resolved and FDA proposed on 30 April 2026 to exclude both from the 503B bulks list, restricting bulk compounding by outsourcing facilities. Narrow patient-specific 503A compounding may remain available. This page assesses no entity's compliance.

Does this page allege anything about Nephron Pharmaceuticals?

No. It reports federal register status with its source and date, and lists what remains unverified. No violation, finding, or concern is asserted.

Sources

Update history

Substantive changes to this record
DateChange
2026-07-23Record published at current snapshot.

Dates change only for substantive updates. Entities may submit a correction or response through the right-to-respond process.